would the slow enrollment suggest a smaller market or lower reception for metric study?
fast enrollment in melanoma is a good thing, but this is a crowd field, without significant benefits there could be a tough approval process and difficulties in sales. Adding varli is a trick they are playing, it might suggest the opposite to your wish.
Hope you can convince the management what they don't know about the company and make them buy some shares, esp the CFO, with the money he made from last offering.
Thanks for the response and insight. It's been more than a year, close to one and half, since they wanted to open sites in Europe. Not a good thing.
i read the interview on the Targeted Oncology website. Besides what's described in your first paragraph summary, there is no mention of melanoma trial or checkpoint inhibitors.
What's going on with Metric study? The management said a few times that the trial would open new sites in Europe during first quarter this year. It has not happened. Without Europe, can they still get enough patients to have a readout this year?